Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics

Overview

Journal Children (Basel)

Specialty Health Services

Date 2024 Nov 27

PMID 39594898

Authors

Keyi Ren

Yu Wang

Minmin Zhang

Ting Tao

Zeyu Sun

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma (NB) is the most common type of extracranial solid tumors in children. Despite the advancements in treatment strategies over the past years, the overall survival rate in patients within the high-risk NB group remains less than 50%. Therefore, new treatment options are urgently needed for this group of patients. Compared with genomic aberrations, proteomic alterations are more dynamic and complex, as well as more directly related to pathological phenotypes and external perturbations such as environmental changes and drug treatments. This review focuses on specific examples of proteomics application in various fundamental aspects of NB research, including tumorigenesis, drug treatment, drug resistance, and highlights potential protein signatures and related signaling pathways with translational values for clinical practice. Moreover, emerging cutting-edge proteomic techniques, such as single cell and spatial proteomics, as well as mass spectrometry imaging, are discussed for their potentials to probe intratumor heterogeneity of NB.

References

Forbes M, Kempa R, Mastrobuoni G, Rayman L, Pietzke M, Bayram S . L-Glyceraldehyde Inhibits Neuroblastoma Cell Growth via a Multi-Modal Mechanism on Metabolism and Signaling. Cancers (Basel). 2024; 16(9). PMC: 11083149. DOI: 10.3390/cancers16091664. View

Morretta E, Belvedere R, Petrella A, Spallarossa A, Rapetti F, Bruno O . Novel insights on the molecular mechanism of action of the anti-angiogenic pyrazolyl-urea GeGe-3 by functional proteomics. Bioorg Chem. 2021; 115:105168. DOI: 10.1016/j.bioorg.2021.105168. View

Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I . Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(12):1617-1629. DOI: 10.1016/S1470-2045(18)30578-3. View

Hong D, Kang Y, Borad M, Sachdev J, Ejadi S, Lim H . Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020; 122(11):1630-1637. PMC: 7251107. DOI: 10.1038/s41416-020-0802-1. View

Omenn G . Strategies for plasma proteomic profiling of cancers. Proteomics. 2006; 6(20):5662-73. DOI: 10.1002/pmic.200600331. View

Wu Z, Hundsdoerfer P, Schulte J, Astrahantseff K, Boral S, Schmelz K . Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging. Cancers (Basel). 2021; 13(13). PMC: 8269054. DOI: 10.3390/cancers13133184. View

Johnsen J, Dyberg C, Fransson S, Wickstrom M . Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacol Res. 2018; 131:164-176. DOI: 10.1016/j.phrs.2018.02.023. View

Sahu D, Hsu C, Lin C, Yang T, Hsu W, Ho S . Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Oncotarget. 2016; 7(36):58022-58037. PMC: 5295409. DOI: 10.18632/oncotarget.11158. View

Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N . Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2008; 15(1):67-78. DOI: 10.1016/j.ccr.2008.12.005. View

10.

Elias J, Gygi S . Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007; 4(3):207-14. DOI: 10.1038/nmeth1019. View

11.

Kaczanowska S, Murty T, Alimadadi A, Contreras C, Duault C, Subrahmanyam P . Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2023; 42(1):35-51.e8. PMC: 10947809. DOI: 10.1016/j.ccell.2023.11.011. View

12.

Kim H, Lee J, Park K, Kim W, Roh G . A mitochondrial division inhibitor, Mdivi-1, inhibits mitochondrial fragmentation and attenuates kainic acid-induced hippocampal cell death. BMC Neurosci. 2016; 17(1):33. PMC: 4902937. DOI: 10.1186/s12868-016-0270-y. View

13.

Nguyen R, Wang H, Sun M, Lee D, Peng J, Thiele C . Combining selinexor with alisertib to target the p53 pathway in neuroblastoma. Neoplasia. 2022; 26:100776. PMC: 8866064. DOI: 10.1016/j.neo.2022.100776. View

14.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

15.

Arias-Hidalgo C, Juanes-Velasco P, Landeira-Vinuela A, Garcia-Vaquero M, Montalvillo E, Gongora R . Single-Cell Proteomics: The Critical Role of Nanotechnology. Int J Mol Sci. 2022; 23(12). PMC: 9224324. DOI: 10.3390/ijms23126707. View

16.

Kohno M, Pouyssegur J . Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006; 38(3):200-11. DOI: 10.1080/07853890600551037. View

17.

Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K . Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways. Sci Signal. 2018; 11(557). DOI: 10.1126/scisignal.aar5680. View

18.

Shi H, Tao T, Abraham B, Durbin A, Zimmerman M, Kadoch C . ARID1A loss in neuroblastoma promotes the adrenergic-to-mesenchymal transition by regulating enhancer-mediated gene expression. Sci Adv. 2020; 6(29):eaaz3440. PMC: 7439613. DOI: 10.1126/sciadv.aaz3440. View

19.

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

20.

Arlt B, Zasada C, Baum K, Wuenschel J, Mastrobuoni G, Lodrini M . Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. Int J Cancer. 2020; 148(5):1219-1232. DOI: 10.1002/ijc.33423. View